Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0F4SN
|
|||
| Former ID |
DIB002719
|
|||
| Drug Name |
KUR-111
|
|||
| Synonyms |
I-0401; I-040302; TGplPTH1-34; Fibrin-PTH (bone cysts), Kuros; Human parathyroid hormone (PTH) + TISSEEL fibrin sealant + hydroxyapatite/tri-calcium phosphate granules (bone fracture), Kuros/Baxter
Click to Show/Hide
|
|||
| Indication | Bone disease [ICD-11: FC0Z; ICD-10: XIII] | Phase 2 | [1] | |
| Company |
Kuros Biosurgery AG
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Parathyroid hormone (PTH) | Target Info | Modulator | [2] |
| Reactome | Class B/2 (Secretin family receptors) | |||
| G alpha (s) signalling events | ||||
| WikiPathways | Endochondral Ossification | |||
| Osteoblast Signaling | ||||
| Vitamin D Receptor Pathway | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| Vitamin D Metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00459641) Safety and Tolerability of I-040302 in Children and Young Adults With Solitary Bone Cysts. U.S. National Institutes of Health. | |||
| REF 2 | Company report (Cytos) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.